High-Dose Baricitinib for Severe Alopecia Areata with Suboptimal Response to Conventional Therapy: A Real-World Assessment
Clinical, Cosmetic and Investigational Dermatology · 2026-06 · Volume 19 · 1-10
DOI: 10.2147/ccid.s604762 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical, Cosmetic and Investigational Dermatology, 2026-06. Verfasst von Qinsi Liu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology & Cosmetic Medicine Center, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, 400010, People's Rep…. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Background
Severe alopecia areata (AA) causes substantial psychosocial burden, with suboptimal response rates to approved baricitinib 4 mg. Pharmacologic strategies for dose escalation, supported by inter-specialty evidence, may address this therapeutic gap.
Aim
To evaluate efficacy and safety of baricitinib 6 mg daily in severe, refractory AA patients who showed suboptimal response to conventional therapies.
Methods
In this retrospective study, four females (mean age 26.5 years) with severe AA (mean baseline Severity of Alopecia Tool, SALT 64.5) received baricitinib 6 mg between January 2023 and June 2025. Efficacy was assessed via serial SALT score changes; safety through standardized laboratory monitoring.
Results
Following escalation to baricitinib 6 mg daily, clinically meaningful SALT improvement was achieved in three patients (75%). Transient laboratory abnormalities occurred in 3 patients (75%), including asymptomatic mild platelet count elevation, self-resolving mild anemia (within normal ranges) and asymptomatic creatinine elevation. No severe adverse events occurred.
Conclusion
Baricitinib 6 mg daily demonstrated enhanced efficacy in 75% of patients with severe refractory AA and exhibited an acceptable short-term safety profile under close monitoring. These findings support further investigation of step-up dosing strategies in randomized controlled trials.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Dermatology & Cosmetic Medicine Center, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, 400010, People's Republic of China.
Zitieren
APA
Liu, Q., Sun, M., Cao, Y., & Zhao, H. (2026). High-Dose Baricitinib for Severe Alopecia Areata with Suboptimal Response to Conventional Therapy: A Real-World Assessment. Clinical, Cosmetic and Investigational Dermatology, Volume 19, 1-10. https://doi.org/10.2147/ccid.s604762
Vancouver
Liu Q, Sun M, Cao Y, Zhao H. High-Dose Baricitinib for Severe Alopecia Areata with Suboptimal Response to Conventional Therapy: A Real-World Assessment. Clinical, Cosmetic and Investigational Dermatology. 2026;Volume 19:1-10. doi:10.2147/ccid.s604762
BibTeX
@article{Liu2026,
author = {Liu, Qinsi and Sun, Mang and Cao, Yuwei and Zhao, Hengguang},
title = {High-Dose Baricitinib for Severe Alopecia Areata with Suboptimal Response to Conventional Therapy: A Real-World Assessment},
journal = {Clinical, Cosmetic and Investigational Dermatology},
year = {2026},
volume = {Volume 19},
pages = {1--10},
doi = {10.2147/ccid.s604762}
}
EUVIMED